I agree that this site is using cookies. You can find further informations here.
X
Andrillon, Anais
21  results:
Search for persons X
?
1

Dose optimization for cancer treatments with considerations..:

Biard, Lucie ; Andrillon, Anaïs ; Silva, Rebecca B.
Clinical Trials.  21 (2024)  3 - p. 322-330 , 2024
Link: https://doi.org/10.1177/..
 
?
2

Incorporating patient-reported outcomes in dose-finding cli..:

Andrillon, Anaïs ; Biard, Lucie ; Lee, Shing M.
Journal of Biopharmaceutical Statistics.  , 2023
Link: https://doi.org/10.1080/..
 
?
3

Surv‐CRM‐12: A Bayesian phase I/II survival CRM for right‐c..:

Andrillon, Anaïs ; Chevret, Sylvie ; Lee, Shing M..
Statistics in Medicine.  41 (2022)  29 - p. 5753-5766 , 2022
Link: https://doi.org/10.1002/..
 
?
4

Lower Relapses Rate With Infliximab Versus Adalimumab in Si..:

Maalouf, Georgina ; Andrillon, Anaïs ; Leclercq, Mathilde...
American Journal of Ophthalmology.  238 (2022)  - p. 173-180 , 2022
Link: https://doi.org/10.1016/..
 
?
5

Mogamulizumab induces long‐term immune restoration and resh..:

Roelens, Marie ; de Masson, Adèle ; Andrillon, Anais...
British Journal of Dermatology.  186 (2022)  6 - p. 1010-1025 , 2022
Link: https://doi.org/10.1111/..
 
?
6

Mogamulizumab induces long term immune restoration and resh..:

Roelens, Marie ; de Masson, Adèle ; Andrillon, Anais...
European Journal of Cancer.  156 (2021)  - p. S19 , 2021
Link: https://doi.org/10.1016/..
 
?
7

Dose-finding design and benchmark for a right censored endp..:

Andrillon, Anaïs ; Chevret, Sylvie ; Lee, Shing M.
Journal of Biopharmaceutical Statistics.  30 (2020)  6 - p. 948-963 , 2020
Link: https://doi.org/10.1080/..
 
?
8

Performance of propensity score matching to estimate causal..:

Andrillon, Anais ; Pirracchio, Romain ; Chevret, Sylvie
Statistical Methods in Medical Research.  29 (2020)  3 - p. 644-658 , 2020
Link: https://doi.org/10.1177/..
 
?
9

Incorporating patient-reported outcomes in dose-finding cli..:

Andrillon, Anaïs ; Biard, Lucie ; Lee, Shing M
http://arxiv.org/abs/2303.17705.  , 2023
Link: http://arxiv.org/abs/230..
 
?
10

Surv‐CRM‐12: A Bayesian phase I/II survival CRM for right‐c..:

Andrillon, Anaïs ; Chevret, Sylvie ; Lee, Shing M.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691552/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
11

Anti-TNF-α versus tocilizumab in the treatment of refractor..:

Leclercq, Mathilde ; Andrillon, Anaïs ; Maalouf, Georgina...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ophtha.2021.11.013.  , 2021
Link: https://hal.univ-lorrain..
 
?
12

Anti-TNF-α versus tocilizumab in the treatment of refractor..:

Leclercq, Mathilde ; Andrillon, Anaïs ; Maalouf, Georgina...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ophtha.2021.11.013.  , 2021
Link: https://hal.univ-lorrain..
 
?
13

Anti-TNF-α versus tocilizumab in the treatment of refractor..:

Leclercq, Mathilde ; Andrillon, Anaïs ; Maalouf, Georgina...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ophtha.2021.11.013.  , 2021
Link: https://hal.univ-lorrain..
 
?
14

Anti-TNF-α versus tocilizumab in the treatment of refractor..:

Leclercq, Mathilde ; Andrillon, Anaïs ; Maalouf, Georgina...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ophtha.2021.11.013.  , 2021
Link: https://hal.univ-lorrain..
 
?
15

Anti-TNF-α versus tocilizumab in the treatment of refractor..:

Leclercq, Mathilde ; Andrillon, Anaïs ; Maalouf, Georgina...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ophtha.2021.11.013.  , 2021
Link: https://hal.univ-lorrain..
 
1-15